Keratoconjunctivitis sicca (dry eye) develop when the eye is unable to maintain a healthy coating of tears. Keratoconjunctivitis sicca (dry eye) can affect any age, and is more common in women than in men. It results in symptoms of discomfort such as visual disturbance and tear film instability (DEWS, 2007). The most common symptoms of Keratoconjunctivitis sicca (dry eye) are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities.
The report includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Keratoconjunctivitis sicca (Dry Eye).
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies discussed in this clinical trials report includes Novartis AG, Allergan, Inc., Santen Pharmaceutical Co., Ltd., Valeant Pharmaceuticals International, Inc., Innovative Medical Products, Otsuka Holdings Co., Ltd., Merck & Co., Inc., ORA, Inc., Pfizer Inc., Laboratoires Thea S.A.
This report also includes the clinical trial overview of top institutes and government that includes Kyoto Prefectural University of Medicine, Keio University, University of Texas Southwestern Medical Center at Dallas, Marshall B. Ketchum University, Federal University of Sao Paulo, Massachusetts Eye and Ear Infirmary, Ophthalmic Consultants of Long Island, Instituto Universitario de Oftalmobiología Aplicada, Wenzhou Medical College, Marui Eye Clinic.
